Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study

被引:27
作者
Tsai, Ching-Wei [1 ,2 ,3 ]
Huang, Han-Chun [1 ]
Chiang, Hsiu-Yin [1 ]
Chung, Chih-Wei [1 ]
Chang, Shih-Ni [1 ]
Chu, Pei-Lun [4 ,5 ]
Kuo, Chin-Chi [1 ,2 ,3 ]
机构
[1] China Med Univ Hosp, Big Data Ctr, Taichung, Taiwan
[2] China Med Univ Hosp, Div Nephrol, Dept Internal Med, Taichung, Taiwan
[3] China Med Univ, Coll Med, Taichung, Taiwan
[4] Fu Jen Catholic Univ Hosp, Dept Internal Med, Div Nephrol, New Taipei, Taiwan
[5] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan
关键词
lipid profile; longitudinal trajectory; chronic kidney disease; dialysis; mortality; electronic medical records; CHRONIC KIDNEY-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; CHRONIC-RENAL-FAILURE; LDL CHOLESTEROL; RISK; DYSLIPIDEMIA; PROGRESSION; MORTALITY; DYSFUNCTION; MANAGEMENT;
D O I
10.1194/jlr.P084590
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Studies on the effects of longitudinal lipid trajectories on end-stage renal disease (ESRD) development and deaths among patients with chronic kidney disease (CKD) are limited. We conducted a registry-based prospective study using data from a 13-year multidisciplinary pre-ESRD care program. The final study population comprised 4,647 patients with CKD. Using group-based trajectory modeling, we dichotomized longitudinal trajectories of total cholesterol (T-CHO), triglyceride (TG), LDL cholesterol (LDL-C), and HDL cholesterol (HDL-C). Time to ESRD or death was analyzed using multiple Cox regression. At baseline, higher levels of T-CHO and LDL-C were associated with rapid progression to ESRD, whereas only HDL-C was positively associated with all-cause mortality [adjusted hazard ratio (HR), 1.20; 95% CI, 1.06-1.36; P-value, 0.005]. Compared with those with a normal T-CHO trajectory, the fully adjusted HR of patients with a high T-CHO trajectory for ESRD risk was 1.21 (P-value, 0.019). Subgroup analysis showed that a high TG trajectory was associated with a 49% increase in mortality risk in CKD patients without diabetes (P-value for interaction, 0.012). In contrast to what was observed based on baseline HDL-C, patients with a trajectory of frequent hypo-HDL cholesterolemia had higher risk of all-cause mortality (adjusted HR, 1.53; P-value, 0.014). Thus, only T-CHO, both at baseline and over the longitudinal course, demonstrated a significant potential risk of incident ESRD. The inconsistency in the observed directions of association between baseline levels and longitudinal trajectories of HDL-C warrants further research to unveil specific pathogenic mechanisms underlying the HDL-C metabolism in patients with CKD.
引用
收藏
页码:648 / 660
页数:13
相关论文
共 60 条
[1]   Low-density lipoprotein cholesterol estimation by a new formula in Indian population [J].
Anandaraja, S ;
Narang, R ;
Godeswar, R ;
Laksmy, R ;
Talwar, KK .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 102 (01) :117-120
[2]   Introduction [J].
不详 .
DIABETES CARE, 2017, 40 :S1-S130
[3]   The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J].
Baigent, Colin ;
Landray, Martin J. ;
Reith, Christina ;
Emberson, Jonathan ;
Wheeler, David C. ;
Tomson, Charles ;
Wanner, Christoph ;
Krane, Vera ;
Cass, Alan ;
Craig, Jonathan ;
Neal, Bruce ;
Jiang, Lixin ;
Hooi, Lai Seong ;
Levin, Adeera ;
Agodoa, Lawrence ;
Gaziano, Mike ;
Kasiske, Bertram ;
Walker, Robert ;
Massy, Ziad A. ;
Feldt-Rasmussen, Bo ;
Krairittichai, Udom ;
Ophascharoensuk, Vuddidhej ;
Fellstrom, Bengt ;
Holdaas, Hallvard ;
Tesar, Vladimir ;
Wiecek, Andrzej ;
Grobbee, Diederick ;
de Zeeuw, Dick ;
Gronhagen-Riska, Carola ;
Dasgupta, Tanaji ;
Lewis, David ;
Herrington, William ;
Mafham, Marion ;
Majoni, William ;
Wallendszus, Karl ;
Grimm, Richard ;
Pedersen, Terje ;
Tobert, Jonathan ;
Armitage, Jane ;
Baxter, Alex ;
Bray, Christopher ;
Chen, Yiping ;
Chen, Zhengming ;
Hill, Michael ;
Knott, Carol ;
Parish, Sarah ;
Simpson, David ;
Sleight, Peter ;
Young, Alan ;
Collins, Rory .
LANCET, 2011, 377 (9784) :2181-2192
[4]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[5]   High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among US Veterans [J].
Bowe, Benjamin ;
Xie, Yan ;
Xian, Hong ;
Balasubramanian, Sumitra ;
Zayed, Mohamed A. ;
Al-Aly, Ziyad .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (10) :1784-1793
[6]   Disorders of Lipid Metabolism in Chronic Kidney Disease [J].
Bulbul, Mustafa C. ;
Dagel, Tuncay ;
Afsar, Baris ;
Ulusu, Nuray N. ;
Kuwabara, Masanarini ;
Covic, Adrian ;
Kanbay, Mehmet .
BLOOD PURIFICATION, 2018, 46 (02) :144-152
[7]  
Cases A, 2005, KIDNEY INT, V68, P87
[8]   Hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic Kidney Disease [J].
Chawla, Varun ;
Greene, Tom ;
Beck, Gerald J. ;
Kusek, John W. ;
Collins, Allan J. ;
Sarnak, Mark J. ;
Menon, Vandana .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (09) :1582-1587
[9]  
Chen SR, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053662, 10.1371/journal.pone.0056380]
[10]   Mechanisms and clinical implications of lipid disorders in chronic kidney disease [J].
Chmielewski, Michal ;
Rutkowski, Boleslaw ;
Lindholm, Bengt .
CLINICAL LIPIDOLOGY, 2009, 4 (04) :449-456